<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title-group>
        <journal-title>Emerging Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">14725264</article-id>
      <article-id pub-id-type="pmc">3035530</article-id>
      <article-id pub-id-type="publisher-id">03-0480</article-id>
      <article-id pub-id-type="doi">10.3201/eid0911.030480</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Human Granulocytic Ehrlichiosis in Estonia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Pr&#xFC;kk</surname>
            <given-names>Tiina</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ainsalu</surname>
            <given-names>Kylliki</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Laja</surname>
            <given-names>Ene</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">&#x2021;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aigro</surname>
            <given-names>Ada</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">&#x2021;</xref>
        </contrib>
        <aff id="aff1"><label>*</label>University of Tartu, Tartu, Estonia</aff>
        <aff id="aff2"><label>&#x2020;</label>Internal Medicine Clinic of Tartu University, Tartu, Estonia</aff>
        <aff id="aff3"><label>&#x2021;</label>United Laboratories of Tartu University Clinics, Tartu, Estonia</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: T. Pr&#xFC;kk, Department of Infectious Diseases, University of Tartu, Lina 6,51004, Tartu, Estonia; fax: 372 7 374232; email: <email xlink:href="tiinap@cut.ee">tiinap@cut.ee</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2003</year>
      </pub-date>
      <volume>9</volume>
      <issue>11</issue>
      <fpage>1499</fpage>
      <lpage>1500</lpage>
    </article-meta>
  </front>
  <body>
    <p><bold>To the Editor:</bold> We report a case of a 24-year-old woman living in a rural area of Estonia who had weakness, chills, and diarrhea on May 10, 2002. On day 5 of the illness, she was admitted to the Department of Infectious Diseases, University of Tartu, with high fever (38.5&#xB0;C) and muscle pains throughout her body. Examination showed mild jaundice, painful and enlarged liver, and inability to move. Throat was erythematous, and enlarged lymphnodes were palpatable on the neck.</p>
    <p>Laboratory findings included the following: leukopenia 2.04x10<sup>9</sup>/L; erythrocytes 4.08x10<sup>12</sup>/L; hemoglobin 130 g/L; thrombocytopenia 36x10<sup>9</sup>/L; eosinophils 0%; basophils 1.0%; monocytes 7.5%; lymphocytes 38.0%; neutrophils 51.0%; reactive lymphcytes 2.0%; plasma cells 0.5%; C-reactive protein 38 mg/L (normal &lt;5 mg/L); bilirubin 95 &#x3BC;mol/L (normal &lt;17 &#x3BC;mol/L); aspartate aminotransferase 121 U/L (normal &lt;31 U/L); alanine aminotransferase 108 UL (normal &lt;31 U/L); and alcaline phosphatase 200 U/L (normal 35&#x2013;104 U/L). Ehrlichiosis was suspected by clinical symptoms and leukopenia, thrombocytopenia, and elevated transaminases.</p>
    <p>Human granulocytic ehrlichiosis (HGE) is an emerging tick-borne disease described for the first time in 1994 in the United States (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>). The first European case of HGE was reported in Slovenia in 1996 (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>). Infection with <italic>Ehrlichia phagocytophila,</italic> the agent of HGE, occurs in areas endemic for <italic>Borrelia burgdorferi</italic> (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>). In Estonia, Lyme borrreliosis is frequently diagnosed in humans but the occurrence of ehrlichiosis has not been established for this region, despite our having found some seropositive results in Lyme borrreliosis patients (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>).</p>
    <p>This case of ehrlichiosis is the first diagnosed in Estonia. The initial diagnosis was based on a typical clinical spectrum of symptoms and clinical laboratory findings, which are relatively nonspecific, making the diagnosis problematic (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>). Polymerase chain reaction results for <italic>Ehrlichia</italic> were negative, and we did not find morula in the blood smear. Indirect immunofluorescence assay (IFA, MRL Diagnostics, Cypress, CA) was used as a confirmatory serologic test. However, results of this assay are often negative during the initial phase of the disease (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>,<xref ref-type="bibr" rid="R6"><italic>6</italic></xref>). On day 7 of illness, the serologic results for immunoglobulin (Ig) M type antibodies to <italic>Ehrlichia</italic> were positive (1:20) and negative for IgG. The diagnosis of ehrlichiosis was established, and therapy with doxycycline was started. After 4 days, the patient became afebrile, and on day 6 she left for home. One month later, the titers of both types of antibodies to <italic>Ehrlichia</italic> were increased: IgM titer was 1:160 and IgG titer was 1:128; 6 months later, IgM antibodies were negative, and the IgG titer remained unchanged.</p>
    <p>Our patient had a typical spectrum of clinical and laboratory changes to <italic>Ehrlichia,</italic> but not very specific findings of infection with <italic>E.</italic> <italic>phagocytophila</italic>. The results of IFA, i.e., IgM antibodies in the beginning of the disease and increasing titer of IgG antibodies during the course of the disease, confirmed the diagnosis. Granulocytic ehrlichiosis should be considered in patients with tick-associated fever.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p><italic>Suggested citation for this article:</italic> Pr&#xFC;kk T, Ainsalu K, Laja E, Aigro A. Human granulocytic ehrlichiosis in Estonia. Emerg Infect Dis [serial online] 2003 Nov [<italic>date cited</italic>]. Available from: URL: <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/ncidod/EID/vol9no11/03-0480.htm">http://www.cdc.gov/ncidod/EID/vol9no11/03-0480.htm</ext-link></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Bakken</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Dumler</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>SM</given-names></string-name>, <string-name><surname>VanEtta</surname> <given-names>LL</given-names></string-name>, <string-name><surname>Eckman</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Walker</surname> <given-names>DH</given-names></string-name> <article-title>Human granulocytic ehrlichiosis in the United States: a new species emerging?</article-title> <source>JAMA</source>. <year>1994</year>;<volume>272</volume>:<fpage>212</fpage>&#x2013;<lpage>8</lpage> <pub-id pub-id-type="doi">10.1001/jama.272.3.212</pub-id><pub-id pub-id-type="pmid">8022040</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Petrovec</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lotric-Furlan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Avsic-Zupanc</surname> <given-names>T</given-names></string-name>, <string-name><surname>Strle</surname> <given-names>F</given-names></string-name>, <string-name><surname>Brouqui</surname> <given-names>P</given-names></string-name>, <string-name><surname>Roux</surname> <given-names>V</given-names></string-name>, <etal/> <article-title>Human disease in Europe caused by a granulocytic <italic>Ehrlichia</italic> species.</article-title> <source>J Clin Microbiol</source>. <year>1997</year>;<volume>35</volume>:<fpage>1556</fpage>&#x2013;<lpage>9</lpage><pub-id pub-id-type="pmid">9163481</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Bj&#xF6;ersdorff</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wittesjo</surname> <given-names>B</given-names></string-name>, <string-name><surname>Berglund</surname> <given-names>I</given-names></string-name>, <string-name><surname>Massung</surname> <given-names>RF</given-names></string-name>, <string-name><surname>Eliasson</surname> <given-names>I</given-names></string-name> <article-title>Human granulocytic ehrlichiosis as a common cause of tick-associated fever in Southeast Sweden: report from a prospective clinical study.</article-title> <source>Scand J Infect Dis</source>. <year>2002</year>;<volume>34</volume>:<fpage>187</fpage>&#x2013;<lpage>91</lpage> <pub-id pub-id-type="doi">10.1080/00365540110080061</pub-id><pub-id pub-id-type="pmid">12030391</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <mixed-citation publication-type="confproc"><string-name><surname>Pr&#xFC;kk</surname> <given-names>T</given-names></string-name>, <string-name><surname>Nilsson</surname> <given-names>I</given-names></string-name>, <string-name><surname>Bj&#xF6;ersdorff</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wadstr&#xF6;m</surname> <given-names>T</given-names></string-name> Seroprevalence of ehrlichiosis in south-Estonia. Budapest: First Congress of the European Society for Emerging Infections; <year>1998</year></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Lotric-Furlan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Avsic-Zupanc</surname> <given-names>T</given-names></string-name>, <string-name><surname>Petrovec</surname> <given-names>M</given-names></string-name>, <string-name><surname>Nicholson</surname> <given-names>WL</given-names></string-name>, <string-name><surname>Sumner</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Childs</surname> <given-names>JE</given-names></string-name>, <etal/> <article-title>Clinical and serological follow-up of patients with human granulocytic ehrlichiosis in Slovenia.</article-title> <source>Clin Diagn Lab Immunol</source>. <year>2001</year>;<volume>8</volume>:<fpage>899</fpage>&#x2013;<lpage>903</lpage><pub-id pub-id-type="pmid">11527800</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Olano</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Walker</surname> <given-names>DH</given-names></string-name> <article-title>Human ehrlichioses: diagnostic challenges and therapeutic recommendations.</article-title> <source>Infect Med</source>. <year>2002</year>;<volume>19</volume>:<fpage>318</fpage>&#x2013;<lpage>25</lpage></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
